$0.46
+4.38%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.46
From 52W high−69.14%
Volume733943.00
Market cap$127.73M
P/E (TTM)—
P/S (TTM)60.2x
Div yield—
Key dataNov 4, 2026
Open
$0.46
From 52W high
−69.14%
Volume
733943.00
Market cap
$127.73M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
43.8
MomentumView details →
1D Return
+4.38%
YTD Return
−56.51%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte announced that it will release financial results for the three and nine months ended September 30, 2026, on November 10, 2026.2d agoHumacyte shares fell 13.01% to $0.41 from the prior session's close.5d agoHumacyte, Inc. said a new U.S. patent covering manufacturing, sterilization, storage and shipping aspects of Symvess and other bioengineered tissues was issued, providing coverage into 2043.7d ago